Oncology Supply shared on LinkedIn:
“As cancer care becomes more personalized and advanced – from CAR-T therapies and bispecific antibodies to precision medicines – getting these innovations to patients requires much more than regulatory approval.
Successful launches now depend on aligning entire healthcare systems, generating compelling evidence for regulators and payers, leveraging real-world evidence, and navigating reimbursement and operational barriers that can delay access for years.
Thank you to Dr. Shushan Hovsepyan and OncoDaily for the opportunity to discuss how the launch of innovative oncology therapies is evolving in today’s increasingly complex healthcare environment.”
Making Innovative Oncology Therapies Accessible for All Patients: Tommy Bramley
